Investments and investor services
FTSE100 drops as miners weigh...again
The miners were again at the bottom of the index, as a lower oil price weighed on metal prices.
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 11 of 11
FTSE100 flat; CityFibre to take on BT Openreach
The FTSE100 was three points lower at lunch at 5,949.
AstraZeneca in deal talks with Acerta Pharma
Last week, reports said the pharma giant was in “advanced talks” to buy Acerta for around US$5bn
South Africans lead FTSE 100 rebound
After heavy losses Friday, FTSE 100 added 48 to 6,001
Investments and investor services
Brokers: Mixed day for the retailers
Dixons Carphone and Dunelm were given the thumbs up, while Kingfisher and next were downgraded by broker Nomura
Investments and investor services
FTSE100 gains 25, Shire rises on M&A chatter
The FTSE100 could only manage a 25 point gain to 6,420.
AstraZeneca gets big upgrade from Morgan Stanley
Shares in big cap pharma AstraZeneca gained ground midweek as heavyweight broker Morgan Stanley said the sector was now fairly valued.
FTSE 100 consolidates early gains
FTSE 100 was 21 points higher at 6,416 ahed of the US opening
Pfizer agrees US$150bn Allergan merger
The combined group will become the world’s largest drug company.
Investors urged to take closer look at Astra’s lupus drug trial
AstraZeneca, Premier Oil, Man Group, and Genus are in the broker spotlight on Thursday
M&A boom looms in life science industry
Some 94% of companies in a survey plan to make acquisitions in the coming year
FTSE100 closes lower after strong US jobs number
The US economy added 271,000 jobs in October compared to forecasts of around 180,000
More M&A to follow AstraZeneca tie-up with ZS Pharma
Companies likely to do bolt-on deals as well as big takeovers
Investments and investor services
US job hopes boost markets in London and Asia
The FTSE 100 Index climbed four points to 6368 in early trading
AstraZeneca to buy US drug firm ZS Pharma for $2.7bn
ZS Pharma is developing a drug to treat high potassium levels in the bloodstream
Archive
FTSE100 closes lower as Anglo American tumbles
After a brief foray into the black, Footsie went lower.....
Blue-chips bounce back after Bank of England rate decision
The FTSE 100 Index pared losses to stand 1.5 points up at 6414 by lunchtime
AstraZeneca upgrade cheers despite Crestor warning
Drug group's shares rise as it forecasts flat annual revenue and higher earnings
Stocks set to claw back the bulk of yesterday's losses
Facebook is set to lead stocks higher after it revealed it had passed the 1bn mark for daily active users.
Miners and Morrisons drag down London market
The FTSE 100 Index was 27.26 points off at 6385 in morning trading
Risers and fallers, including Alliance Pharma, Thoams Cook, TUI AG and OPG Power
Here are some major share risers and fallers at 1.30pm.....
AstraZeneca ups profit guidance but sees tough 2016
The group said total annual revenue would match last year's rather than declining
Thursday's agenda: Top-line disappointment in store for Morrisons and Astra
Not much chance to catch your breath at 7.00am on Thursday, with a cavalcade of company updates scheduled.
AstraZeneca's main headaches: FX, generics and slowing Chinese growth
Currency movements and competition from cheaper generic versions of its drugs means it is most unlikely Astra will keep its growth story going
Week ahead: Marks aims to emulate Next's success
Marks reports on Wednesday, while a host of other companies report alond with a slew of economic data.
AstraZeneca's ovarian drug tests well for prostate cancer
Drug companies are looking at ways to target tumours by genetic mutation rather than where they are in the body.
AstraZeneca gout drug approval seen as mild positive
Hyperuricemia, where an excess of uric acid leads to crystals forming around the joints, causes the disease.
Investments and investor services
Shares stay red as market gives thumbs-down to Glencore
The Footsie fell 35.39 points to 6,380 as bullish sentiment disappeared
London shares fall as markets take stock
Shares in the red as traders ponder next moves ahead of busy week
Archive
AstraZeneca gets shot in the arm from Deutsche
Drugs giant AstraZeneca gets a shot in the arm from broker heavyweight Deutsche today...
Investments and investor services
FTSE 100 swings to 35 point loss
After lunch, investors were not willing to carry much risk into the American session.
Investments and investor services
Risers & Fallers: AstraZeneca, Horizonte Minerals, Active Energy, Regency Mines, KAZ Minerals...
Below are the main news-driven share price movements at 4pm.
Investments and investor services
Crest Nicholson is Goldman's top pick in midst of housing sector's results season
It seems the housing sector has been bouncing back since the current decade began, but brokers seem to agree there is further to go.
AstraZeneca gets new FDA approval for heart drug
Patients can now be given the drug for more than twelve months
Archive
Time to jump on Merlin shares, reckons UBS
Attractions and park operator Merlin Entertainments' share price is now at an attractive level, says Swiss broker UBS...
Woodford fund proving a summer favourite for investors
Bio and pharma holdings keep Woodford on top with other healthcare funds also doing well.
Valeant Pharmaceuticals licenses psoriasis drug from AstraZeneca
After Amgen, the originator of the skin condition treatment, abandoned brodalumab, Astra has called on the Canadian dermatology specialist to develop the drug.
AstraZeneca licenses psoriasis rights to Valeant
After Amgen, the originator of the skin condition treatment, abandoned brodalumab, Astra has called on the Canadian dermatology specialist to develop the drug.
AstraZeneca nabs rival's executive
Dr Sean Bohen is joining on September 15 from Genentech, a Roche subsidiary.
FTSE 100 plummets as China sell-off spooks markets
In the UK, the FTSE 100 was more than 2% lower, 135 points, to 6,051 with not a single constituent managing to eke out a gain.
FTSE 100 has £80bn wiped off on Black Monday
On what some are calling ‘Black Monday’ the FTSE 100 was hit to the tune of £80bn, suffering its worst day since 2009.
Eli Lilly advances after positive results in diabetes study
Shares in Eli Lilly were among the few blue-chips making headway on Thursday after a positive result in a diabetes study.
Analysis: Old vs new, Witan and Woodford release interims
Witan one of the UK’s oldest investment trusts, and Woodford Patient Capital Trust, which listed in April, reported first half figures today
AstraZeneca to pay Inovio Pharma $727 mln to produce cancer vaccine
It is AstraZeneca's third deal in less than a week
Investments and investor services
FTSE 100 flies as Glaxo becomes latest subject of bid gossip
The latest pharma bid rumour to surface is Pfizer gunning for Glaxo, but it was the miners that drove Footsie's ascent
Analysis: Shire dreaming big with Baxalta offer
Baxalta’s board has already shot down the deal as it has refused to enter into talks on the offer but Shire isn’t about to bow out without a fight.
FTSE 100 buoyed by miners and more pharma bid gossip
Rio Tinto led the advance ahead of results due out tomorrow
Investments and investor services
Footsie hits the gas
Shell and InterContinental Hotels were the stand-out stocks on a busy day for trading updates from Footsie firms
Investments and investor services
Rising heavyweight stocks drive up London shares
Royal Dutch Shell and AstraZeneca haul Footsie higher
UPDATE - AstraZeneca expects new products to see off generics
On a constant currency basis, Astra did better. Sales were up 1% and by 2% in the second quarter.
Investments and investor services
London market rides crest of corporate results wave
Shares rise modestly as blue-chips flood market with updates
FTSE100 keeps going well, keeps going Shell
The Anglo-Dutch index heavyweight fuelled gains for the Footsie
Archive
Thursday's agenda - More big cap results, including Rolls and BT
More results today on offer with some more big caps showing how much they are contributing to the UK's current growth trajectory. Lets start with a British stalwart - engineer Rolls Royce which posts second quarter earnings. It's been a tor
Investments and investor services
Week Ahead: Big oil and the banks to dominate
No shortage of big names reporting this week, including the state-controlled lenders Lloyds and RBS, plus integrated oil giants BP and Shell
Clinigen's strategy sees 45% revenue growth in year gone
Pharma and services specialist Clinigen said its year gone had been another "tremendous one", which saw significant organic growth and a revenue rise of more than 45%.
Celgene makes $7.2bn bid for Receptos
Celgene could face battle for Receptos, broker says
Archive
FTSE100 closes higher as all eyes still on Athens
FTSE100 closed positively but just 15 points ahead as traders considered Greece...
London shares fall as traders eye uphill Greek recovery battle
BoE's Carney points to 'big execution risks' in Greek deal.
AstraZeneca wins US approval for cancer drug
US regulators give green light to Iressa treatment for lung cancer
Archive
FTSE100 finishes higher with Greece and BP in the mix
The UK benchmark closed over 21 points to the good at 6,630, with BP top dog, with its shares adding 4.69% to 438.80p.
Archive
London shares edge higher on construction industry cheer
Building industry data help to build trader confidence despite Greece
Shell's a standout opportunity in ‘horrible and trapped’ sector
Shell, BG, and Astrazeneca are among the blue-chips under Thursday's broker spotlight
Archive
Footsie treads water as delays in solving Greek debt saga weigh
Eurogroup rules out more talks with Athens until after referendum
Cancer drug firms to cash in on $9bn immunotherapy market
Trials have shown that immunotherapy may revolutionise cancer treatment
AstraZeneca "to miss out on US drug deal" - sources
Receptos is said to have rebuffed $200 per share bid approach from AstraZeneca
Archive
Broker spotlight, including AstraZeneca, DCC, Homeserve, Circle Oil, Motif Bio ...
US broker Jefferies reckons support services provider DCC (LON:DCC) is firing on all cylinders, and has hiked up the price target to 5,900p from 4,500p previously. The rating is 'buy'.
Investments and investor services
FTSE 100 jumps 50 points early
The FTSE 100 made a big rebound from Friday's fall as it climbed back above 7,000.